<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04554160</url>
  </required_header>
  <id_info>
    <org_study_id>H-18005164</org_study_id>
    <nct_id>NCT04554160</nct_id>
  </id_info>
  <brief_title>Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring</brief_title>
  <acronym>ASPIRE</acronym>
  <official_title>ArrhythmiaS in Pulmonary arterIal hypeRtEnsion and Right Heart Failure Assessed by Continuous Long-term Cardiac Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arrhythmias are considered a prominent phenomenon in pulmonary hypertension (PH) as the&#xD;
      disease progresses. According primarily to retrospective studies with up to 24 hours of&#xD;
      monitoring, supraventricular tachycardias (SVT) can be found in 8-35% of patients, with&#xD;
      significant impact on survival.&#xD;
&#xD;
      Furthermore, a few prospective studies to date deploying short-term monitoring (10 minutes-24&#xD;
      hours) have revealed lower heart rate variability (HRV) in patients with pulmonary arterial&#xD;
      hypertension (PAH).&#xD;
&#xD;
      In ASPIRE arrhythmias and heart rate variability is being assessed via long term monitoring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In general there is a lack of evidence of the arrhythmic burden in PH. The present study is&#xD;
      the first to apply continuous long-term cardiac monitoring in patients with PH to describe&#xD;
      the prevalence of arrhythmias in PH by continuous long-term cardiac monitoring. Furthermore,&#xD;
      the correlation between heart rate variability and risk assessment parameters including WHO&#xD;
      functional class (FC), NT-proBNP, 6MWT, cardiac parameters and cardiac function will be&#xD;
      studies.&#xD;
&#xD;
      A few prospective studies have demonstrated lower HRV in PH than in healthy individuals,&#xD;
      however only based on short-term monitoring (20 minutes to 24 hour) and only in a few&#xD;
      patients. In retrospective studies, a higher mortality in children with PAH and low HRV has&#xD;
      been shown with 24 hour Holter monitoring. Consequently, there is a lack of evidence&#xD;
      regarding right heart failure and the prognostic value of HRV.&#xD;
&#xD;
      Risk assessment in PH is essential in the selection of treatment in PH and for prognosis in&#xD;
      the study ASPIRE the investigators will assess the use of heart rate variability in pulmonary&#xD;
      hypertension.&#xD;
&#xD;
      In conclusion the ASPIRE study will:&#xD;
&#xD;
        1. Assess the incidence and prevalence of arrhythmias using long term cardiac monitoring&#xD;
           via a reveal LINQ loop recorder (Medtronic). Furthermore, the investigators will assess;&#xD;
           Change in cardiac index, right atrial size, RV size, fibrosis and stroke volume.&#xD;
&#xD;
        2. The investigators will assess the arrhythmic burden in relation to:&#xD;
&#xD;
             -  Change in 6 MWT&#xD;
&#xD;
             -  Hemodynamic changes with RHC&#xD;
&#xD;
             -  Hemodynamic changes in echocardiography&#xD;
&#xD;
             -  The number of patients progressing one FC (Modified NYHA class)&#xD;
&#xD;
             -  Changes in NT-proBNP.&#xD;
&#xD;
             -  Hospital admission for any reason&#xD;
&#xD;
             -  Death or transplantation&#xD;
&#xD;
        3. Monitor heart rate variability and address a comparison to known risk markers and CMR&#xD;
           and echocardiography.&#xD;
&#xD;
      The study specifically seeks to investigate following:&#xD;
&#xD;
        -  The incidence and type of supraventricular and ventricular arrhythmias in PH by&#xD;
           continuous long-term monitoring&#xD;
&#xD;
        -  The predictive value of both right and left ventricular cardiac magnetic resonance (CMR)&#xD;
           imaging parameters for arrhythmogenesis in PAH, heart rate variability, and heart rate.&#xD;
&#xD;
        -  Optimization of specific therapy in PAH using continuous long-term arrhythmia monitoring&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence and prevalence of arrhythmias in pulmonary hypertension</measure>
    <time_frame>2022</time_frame>
    <description>Assessed throughout continuous cardiac monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>2022</time_frame>
    <description>Throughout continuous cardiac monitoring heart rate variability will be assessed as a clinical marker. It will be compared with already known clinical markers in pulmonary hypertension and compared with echocardiography and cardiac MR scans.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arrhythmias and their impact on heart function assessed with echocardiography</measure>
    <time_frame>2022</time_frame>
    <description>Change in function of the right and left heart chambers in the patients' with and without arrhythmias assessed with echocardiography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate variability and heart function assessed with CMR scans.</measure>
    <time_frame>2022</time_frame>
    <description>The patients' heart rate variability will be compared to the function of the right and left ventricle (LVEF, RVEF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate variability and chamber sizes assessed CMR scans</measure>
    <time_frame>2022</time_frame>
    <description>The patients' heart rate variability will be compared to the size of the right and left ventricle (ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in heart function when having arrhythmias, assessed with CMR scans.</measure>
    <time_frame>2022</time_frame>
    <description>The patients' arrhythmic burden will be compared to the function of the right and left ventricle (LVEF, RVEF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart size in the group with and without arrhythmias, assessed with CMR scans.</measure>
    <time_frame>2022</time_frame>
    <description>The patients' arrhythmic burden will be compared to the size of the right and left ventricle (ml).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chamber sizes in patients with and without arrhythmias assessed with echocardiography.</measure>
    <time_frame>2022</time_frame>
    <description>Change in echocardiography parameters assess by the size of the right and left heart chambers (ml and cm2) in the patients with and without arrhythmias.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arrhythmias and their impact on WHO functional class</measure>
    <time_frame>2022</time_frame>
    <description>Modified WHO functional class when having arrhythmias</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Arrhythmias and their impact on death or transplantation</measure>
    <time_frame>2022</time_frame>
    <description>Do any patients die because of the arrhythmias and will any patients need a transplantation because of terminal PH and arrhythmias.</description>
  </other_outcome>
  <other_outcome>
    <measure>Arrhythmias impact on specific PAH therapy</measure>
    <time_frame>2022</time_frame>
    <description>How many patients will need escalation in PAH therapy when having arrhythmia and how much of an increase.</description>
  </other_outcome>
  <other_outcome>
    <measure>Arrhythmias impact on six minute walking tests</measure>
    <time_frame>2022</time_frame>
    <description>Arrhythmias impact on reduction in number of meters performed in a six minute walking test during the study period.</description>
  </other_outcome>
  <other_outcome>
    <measure>Arrhythmias and their impact on NT-proBNP</measure>
    <time_frame>2022</time_frame>
    <description>NT-proBNP change during the study period.</description>
  </other_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Arrhythmias, Cardiac</condition>
  <condition>Heart Rate Variability</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Loop recorder implantation</intervention_name>
    <description>A loop recorder is implanted in the start of the study after informed consent is signed and enables continuous cardiac monitoring.</description>
    <other_name>Reveal LINQ loop recorder</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      There willl be taken 10 ml of blood for each visit (6 visits in total), of which the excess&#xD;
      amount will be stored in a biobank. The material is stored for up to 25 years following.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with pulmonary hypertension:&#xD;
&#xD;
        Patients can be in WHO group 1 classified by one of the following subgroups:&#xD;
&#xD;
          -  Idiopathic pulmonary arterial hypertension (IPAH)&#xD;
&#xD;
          -  Heritable pulmonary arterial hypertension (HPAH)&#xD;
&#xD;
          -  Drugs and toxins&#xD;
&#xD;
          -  Associated with (APAH): specifically, connective tissue disease (CTD), HIV infection&#xD;
             and congenital heart disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pulmonary hypertension patients &gt;18 years of age&#xD;
&#xD;
               -  Voluntary participation after giving informed verbal and written consent&#xD;
&#xD;
               -  Patients naïve to PAH-specific treatments&#xD;
&#xD;
               -  Patients on current PAH specific medication independent of duration of therapy&#xD;
&#xD;
               -  Patients can be in WHO group 1 classified by one of the following subgroups:&#xD;
&#xD;
               -  Idiopathic pulmonary arterial hypertension (IPAH)&#xD;
&#xD;
               -  Heritable pulmonary arterial hypertension (HPAH)&#xD;
&#xD;
               -  Drugs and toxins&#xD;
&#xD;
               -  Associated with (APAH): specifically, connective tissue disease (CTD), HIV&#xD;
                  infection and congenital heart disease&#xD;
&#xD;
               -  Diagnosis of PAH confirmed by right heart catheterization&#xD;
&#xD;
               -  WHO/NYHA functional class II to IV symptoms&#xD;
&#xD;
               -  6MWT distances of ≥50 meters and within 15% of each other on 2 consecutive tests&#xD;
                  preferably performed on different days during Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of 3 or more of the following risk factors for heart failure with preserved&#xD;
             ejection fraction at Screening: BMI &gt;30 kg/m2; diabetes mellitus of any type; systemic&#xD;
             hypertension, significant coronary artery disease; or left atrial volume index (LAVi)&#xD;
             &gt;30 mL/m2.&#xD;
&#xD;
          -  Evidence or history of left-sided heart disease and/or clinically significant cardiac&#xD;
             disease.&#xD;
&#xD;
          -  Acutely decompensated heart failure within 30 days prior to Screening&#xD;
&#xD;
          -  Evidence of significant parenchymal lung disease&#xD;
&#xD;
          -  Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure&#xD;
             (SBP) &gt;160 mmHg or sitting diastolic blood pressure (DBP) &gt;100 mmHg at Screening. •&#xD;
             Systolic blood pressure &gt;160 mmHg or &lt; 90 mmHg; or diastolic blood pressure &gt; 100 mgHg&#xD;
             at Screening&#xD;
&#xD;
          -  Male subjects with a corrected QT interval using Fridericia's formula (QTcF) &gt;450&#xD;
             msec, and female subjects with QTcF &gt;470 msec on ECG measured at Screening or&#xD;
             Baseline.&#xD;
&#xD;
          -  Other severe acute or chronic medical or laboratory abnormality that may increase the&#xD;
             risk associated with study participation or that would confound study analysis or&#xD;
             impair study participation or cooperation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jørn Carlsen, MD, DMSC</last_name>
    <role>Study Director</role>
    <affiliation>MD at Copenhagen University Hospital, Rigshospitalet 9- Blegdamsvej</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jørn Carlsen, MD, DMSc, FESC</last_name>
    <phone>(+45) 35458060</phone>
    <email>joern.carlsen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mads Andersen, MD</last_name>
    <phone>(+45) 21636430</phone>
    <email>mads.oerbeak.andersen.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiology 2141 Copenhagen University Hospital, Rigshospitalet 9- Blegdamsvej</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jørn Carlsen, MD, DMSc</last_name>
      <phone>(+45) 35458060</phone>
      <email>joern.carlsen@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50. doi: 10.1016/j.jacc.2013.10.032. Review.</citation>
    <PMID>24355641</PMID>
  </reference>
  <reference>
    <citation>Tongers J, Schwerdtfeger B, Klein G, Kempf T, Schaefer A, Knapp JM, Niehaus M, Korte T, Hoeper MM. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J. 2007 Jan;153(1):127-32.</citation>
    <PMID>17174650</PMID>
  </reference>
  <reference>
    <citation>Wen L, Sun ML, An P, Jiang X, Sun K, Zheng L, Liu QQ, Wang L, Zhao QH, He J, Jing ZC. Frequency of supraventricular arrhythmias in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol. 2014 Nov 1;114(9):1420-5. doi: 10.1016/j.amjcard.2014.07.079. Epub 2014 Aug 13.</citation>
    <PMID>25217453</PMID>
  </reference>
  <reference>
    <citation>Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol. 2013 Sep 1;167(5):2300-5. doi: 10.1016/j.ijcard.2012.06.024. Epub 2012 Jun 22.</citation>
    <PMID>22727973</PMID>
  </reference>
  <reference>
    <citation>Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29.</citation>
    <PMID>26320113</PMID>
  </reference>
  <reference>
    <citation>Wanamaker B, Cascino T, McLaughlin V, Oral H, Latchamsetty R, Siontis KC. Atrial Arrhythmias in Pulmonary Hypertension: Pathogenesis, Prognosis and Management. Arrhythm Electrophysiol Rev. 2018 Mar;7(1):43-48. doi: 10.15420/aer.2018.3.2.</citation>
    <PMID>29636972</PMID>
  </reference>
  <reference>
    <citation>Mercurio V, Peloquin G, Bourji KI, Diab N, Sato T, Enobun B, Housten-Harris T, Damico R, Kolb TM, Mathai SC, Tedford RJ, Tocchetti CG, Hassoun PM. Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. Pulm Circ. 2018 Apr-Jun;8(2):2045894018769874. doi: 10.1177/2045894018769874. Epub 2018 Mar 26.</citation>
    <PMID>29575972</PMID>
  </reference>
  <reference>
    <citation>Cannillo M, Grosso Marra W, Gili S, D'Ascenzo F, Morello M, Mercante L, Mistretta E, Salera D, Zema D, Bissolino A, Fusaro E, Marra S, Libertucci D, Gaita F. Supraventricular Arrhythmias in Patients With Pulmonary Arterial Hypertension. Am J Cardiol. 2015 Dec 15;116(12):1883-9. doi: 10.1016/j.amjcard.2015.09.039. Epub 2015 Oct 9.</citation>
    <PMID>26522342</PMID>
  </reference>
  <reference>
    <citation>Cirulis MM, Ryan JJ, Archer SL. Pathophysiology, incidence, management, and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Pulm Circ. 2019 Jan-Mar;9(1):2045894019834890. doi: 10.1177/2045894019834890.</citation>
    <PMID>30747032</PMID>
  </reference>
  <reference>
    <citation>Rajdev A, Garan H, Biviano A. Arrhythmias in pulmonary arterial hypertension. Prog Cardiovasc Dis. 2012 Sep-Oct;55(2):180-6. doi: 10.1016/j.pcad.2012.06.002. Review.</citation>
    <PMID>23009914</PMID>
  </reference>
  <reference>
    <citation>Folino AF, Bobbo F, Schiraldi C, Tona F, Romano S, Buja G, Bellotto F. Ventricular arrhythmias and autonomic profile in patients with primary pulmonary hypertension. Lung. 2003 Nov-Dec;181(6):321-8.</citation>
    <PMID>14749936</PMID>
  </reference>
  <reference>
    <citation>da Silva Gonçalves Bós D, Van Der Bruggen CEE, Kurakula K, Sun XQ, Casali KR, Casali AG, Rol N, Szulcek R, Dos Remedios C, Guignabert C, Tu L, Dorfmüller P, Humbert M, Wijnker PJM, Kuster DWD, van der Velden J, Goumans MJ, Bogaard HJ, Vonk-Noordegraaf A, de Man FS, Handoko ML. Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. Circulation. 2018 Feb 27;137(9):910-924. doi: 10.1161/CIRCULATIONAHA.117.027451. Epub 2017 Nov 22.</citation>
    <PMID>29167228</PMID>
  </reference>
  <reference>
    <citation>Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. J Am Coll Cardiol. 2008 May 6;51(18):1725-33. doi: 10.1016/j.jacc.2008.01.038. Review.</citation>
    <PMID>18452777</PMID>
  </reference>
  <reference>
    <citation>Vonk Noordegraaf A, Galiè N. The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev. 2011 Dec;20(122):243-53. doi: 10.1183/09059180.00006511. Review.</citation>
    <PMID>22130817</PMID>
  </reference>
  <reference>
    <citation>Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, Torbicki A, Voelkel NF, Hassoun PM. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D22-33. doi: 10.1016/j.jacc.2013.10.027. Review.</citation>
    <PMID>24355638</PMID>
  </reference>
  <reference>
    <citation>Smith B, Genuardi MV, Koczo A, Zou RH, Thoma FW, Handen A, Craig E, Hogan CM, Girard T, Althouse AD, Chan SY. Atrial arrhythmias are associated with increased mortality in pulmonary arterial hypertension. Pulm Circ. 2018 Jul-Sep;8(3):2045894018790316. doi: 10.1177/2045894018790316. Epub 2018 Jul 3.</citation>
    <PMID>29969045</PMID>
  </reference>
  <reference>
    <citation>Li YH, Tholakanahalli Z, Adabag JM, Wang Z, Li J. [Effectiveness and accuracy of arrhythmia detection algorithm with the Reveal LINQ insertable cardiac monitor]. Zhonghua Xin Xue Guan Bing Za Zhi. 2018 Jun 24;46(6):470-474. doi: 10.3760/cma.j.issn.0253-3758.2018.06.011. Chinese.</citation>
    <PMID>29925184</PMID>
  </reference>
  <reference>
    <citation>Wensel R, Jilek C, Dörr M, Francis DP, Stadler H, Lange T, Blumberg F, Opitz C, Pfeifer M, Ewert R. Impaired cardiac autonomic control relates to disease severity in pulmonary hypertension. Eur Respir J. 2009 Oct;34(4):895-901. doi: 10.1183/09031936.00145708. Epub 2009 May 14.</citation>
    <PMID>19443531</PMID>
  </reference>
  <reference>
    <citation>Shaffer F, McCraty R, Zerr CL. A healthy heart is not a metronome: an integrative review of the heart's anatomy and heart rate variability. Front Psychol. 2014 Sep 30;5:1040. doi: 10.3389/fpsyg.2014.01040. eCollection 2014. Review.</citation>
    <PMID>25324790</PMID>
  </reference>
  <reference>
    <citation>Shaffer F, Ginsberg JP. An Overview of Heart Rate Variability Metrics and Norms. Front Public Health. 2017 Sep 28;5:258. doi: 10.3389/fpubh.2017.00258. eCollection 2017. Review.</citation>
    <PMID>29034226</PMID>
  </reference>
  <reference>
    <citation>Smilde TD, van Veldhuisen DJ, van den Berg MP. Prognostic value of heart rate variability and ventricular arrhythmias during 13-year follow-up in patients with mild to moderate heart failure. Clin Res Cardiol. 2009 Apr;98(4):233-9. doi: 10.1007/s00392-009-0747-0. Epub 2009 Feb 13.</citation>
    <PMID>19219394</PMID>
  </reference>
  <reference>
    <citation>Huikuri HV, Stein PK. Heart rate variability in risk stratification of cardiac patients. Prog Cardiovasc Dis. 2013 Sep-Oct;56(2):153-9. doi: 10.1016/j.pcad.2013.07.003. Epub 2013 Aug 12. Review.</citation>
    <PMID>24215747</PMID>
  </reference>
  <reference>
    <citation>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996 Mar 1;93(5):1043-65.</citation>
    <PMID>8598068</PMID>
  </reference>
  <reference>
    <citation>Galinier M, Pathak A, Fourcade J, Androdias C, Curnier D, Varnous S, Boveda S, Massabuau P, Fauvel M, Senard JM, Bounhoure JP. Depressed low frequency power of heart rate variability as an independent predictor of sudden death in chronic heart failure. Eur Heart J. 2000 Mar;21(6):475-82.</citation>
    <PMID>10681488</PMID>
  </reference>
  <reference>
    <citation>Lammers AE, Munnery E, Hislop AA, Haworth SG. Heart rate variability predicts outcome in children with pulmonary arterial hypertension. Int J Cardiol. 2010 Jul 9;142(2):159-65. doi: 10.1016/j.ijcard.2008.12.087. Epub 2009 Jan 26.</citation>
    <PMID>19176261</PMID>
  </reference>
  <reference>
    <citation>Umetani K, Singer DH, McCraty R, Atkinson M. Twenty-four hour time domain heart rate variability and heart rate: relations to age and gender over nine decades. J Am Coll Cardiol. 1998 Mar 1;31(3):593-601.</citation>
    <PMID>9502641</PMID>
  </reference>
  <reference>
    <citation>Florea VG, Cohn JN. The autonomic nervous system and heart failure. Circ Res. 2014 May 23;114(11):1815-26. doi: 10.1161/CIRCRESAHA.114.302589. Review.</citation>
    <PMID>24855204</PMID>
  </reference>
  <reference>
    <citation>Jankowska EA, Ponikowski P, Piepoli MF, Banasiak W, Anker SD, Poole-Wilson PA. Autonomic imbalance and immune activation in chronic heart failure - pathophysiological links. Cardiovasc Res. 2006 Jun 1;70(3):434-45. Epub 2006 Feb 14. Review.</citation>
    <PMID>16480965</PMID>
  </reference>
  <reference>
    <citation>Yi HT, Hsieh YC, Wu TJ, Huang JL, Lin WW, Liang KW, Su CS, Tsai WJ, Wang KY. Heart rate variability parameters and ventricular arrhythmia correlate with pulmonary arterial pressure in adult patients with idiopathic pulmonary arterial hypertension. Heart Lung. 2014 Nov-Dec;43(6):534-40. doi: 10.1016/j.hrtlng.2014.05.010. Epub 2014 Jun 11.</citation>
    <PMID>24929769</PMID>
  </reference>
  <reference>
    <citation>Fauchier L, Babuty D, Melin A, Bonnet P, Cosnay P, Paul Fauchier J. Heart rate variability in severe right or left heart failure: the role of pulmonary hypertension and resistances. Eur J Heart Fail. 2004 Mar 1;6(2):181-5.</citation>
    <PMID>14984725</PMID>
  </reference>
  <reference>
    <citation>Tsai CH, Ma HP, Lin YT, Hung CS, Hsieh MC, Chang TY, Kuo PH, Lin C, Lo MT, Hsu HH, Peng CK, Lin YH. Heart Rhythm Complexity Impairment in Patients with Pulmonary Hypertension. Sci Rep. 2019 Jul 24;9(1):10710. doi: 10.1038/s41598-019-47144-1.</citation>
    <PMID>31341216</PMID>
  </reference>
  <reference>
    <citation>Weatherald J, Boucly A, Sitbon O. Risk stratification in pulmonary arterial hypertension. Curr Opin Pulm Med. 2018 Sep;24(5):407-415. doi: 10.1097/MCP.0000000000000510. Review.</citation>
    <PMID>30004992</PMID>
  </reference>
  <reference>
    <citation>Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation. 2019 May 21;139(21):2440-2450. doi: 10.1161/CIRCULATIONAHA.118.039360.</citation>
    <PMID>30982349</PMID>
  </reference>
  <reference>
    <citation>Sanders P, Pürerfellner H, Pokushalov E, Sarkar S, Di Bacco M, Maus B, Dekker LR; Reveal LINQ Usability Investigators. Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable cardiac monitor: Results from the Reveal LINQ Usability Study. Heart Rhythm. 2016 Jul;13(7):1425-30. doi: 10.1016/j.hrthm.2016.03.005. Epub 2016 Mar 4.</citation>
    <PMID>26961298</PMID>
  </reference>
  <reference>
    <citation>Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014 Apr 25;114(9):1453-68. doi: 10.1161/CIRCRESAHA.114.303211. Review.</citation>
    <PMID>24763464</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Jørn Carlsen</investigator_full_name>
    <investigator_title>Principal investigator, MD, DMSc</investigator_title>
  </responsible_party>
  <keyword>arrhythmias</keyword>
  <keyword>Heart rate variability</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Risk assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT04554160/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

